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INTRODUCTION
Epigenetic regulatory mechanisms involve heritable alterations in
chromatin structure that govern the transcription profile and genome
stability of a cell during animal development or in different disease
states (Meehan et al., 2005). It is well established that modification
of DNA at CpGs by the addition of a methyl group at the 5 position
of cytosine affects gene expression by suppressing the function of
gene regulatory elements, including promoters, enhancers,
insulators and enhancer blockers (Goll and Bestor, 2005). Dynamic
changes in DNA methylation patterns during development or in
cancer cells contribute directly to altered transcription expression
profiles (Gius et al., 2004; Hershko et al., 2003). Targeted mutation
of the gene encoding the maintenance methyltransferase DNMT1 in
mice results in DNA hypomethylation, transcription activation and
embryo lethality that is associated with activation of apoptosis
(Jackson-Grusby et al., 2001; Lei et al., 1996; Li et al., 1992;
Takebayashi et al., 2007). Equally, overexpression of DNMT1 is
incompatible with mouse and amphibian development
(Biniszkiewicz et al., 2002; Stancheva and Meehan, 2000).
Homozygous mutant Dnmt1–/– mouse embryos can be identified as
early as 8.5 days postcoitum (dpc), and by 9.5 dpc they exhibit
severe developmental delay, lack visible somites and display a
distorted neural tube (Lei et al., 1996). This contrasts with Dnmt1–/–
ES cells, which proliferate normally in culture unless they are
induced to differentiate, although they do exhibit high rates of
microsatellite instability (Guo et al., 2004; Jackson-Grusby et al.,
2001). Conditional deletion of DNMT1 in mouse embryonic
fibroblasts (MEFs) results in DNA demethylation and a uniform
p53-dependent cell death (Jackson-Grusby et al., 2001). However,
MEFs with a hypomorphic mutant Dnmt1n/n can proliferate in
culture at normal exponential rates and do not undergo senescence
even after 100 generations in the absence of p53 function (Lande-
Diner et al., 2007). Inactivation of p53 prolongs the proliferative
capacity of Dnmt1 null fibroblasts (Jackson-Grusby et al., 2001).
Despite obvious differences in biology and early developmental
strategies, the phenotype of xDnmt1-deficient Xenopus laevis
embryos shows remarkable similarity to the mouse Dnmt1–/–
phenotype, as indicated by the presence of axial defects, failure to
form a neural tube, and improper patterning of the somites
(Stancheva and Meehan, 2000). In frogs, severe depletion of
maternally expressed xDNMT1p by antisense (AS) RNA results in
the premature transcription of developmentally essential genes and
p53-mediated apoptosis (Stancheva and Meehan, 2000; Stancheva
et al., 2001). One generalisation from the analysis of DNMT1
depletion or inhibition in embryos is that it is not essential for the
survival of embryonic cells during early cleavage stages (Meehan
and Stancheva, 2001). Instead the phenotypical consequences of
disrupting DNMT1 function only become apparent during and after
gastrulation when p53-dependent apoptosis is initiated (Stancheva
et al., 2001). A partial reduction (between 35-50% depletion) in
xDNMT1p levels, which is not enough to result in global changes
in DNA methylation levels, is sufficient for activation of a cell death
program in Xenopus laevis embryos (Dunican et al., 2008). These
observations support the hypothesis that DNMT1 possesses
essential functions that are independent of its role as a maintenance
methyltransferase and links its absence with activation of a cellular
checkpoint response (Brown and Robertson, 2007).
The initiating signals for apoptosis in DNMT1-deficient embryos
are unknown, one hypothesis is that hypomethylation leads to the
release of chromosomal proteins that act as sensors of DNA
methylation levels and induce p53 activation (Stancheva et al.,
2001). Several protein candidates can be considered as sensors,
including methyl-CpG binding proteins (MBD), which bind to
chromatin by a methylation-dependent mechanism (Klose and Bird,
2006). However this model in its crude form would not be
compatible with the dynamic changes in DNA methylation patterns
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that occur during development (Morgan et al., 2005). Special cases
in which normal alterations in methyl-CpG levels would be unable
to trigger apoptosis would need to be in place. Another possibility is
that the signal originates with xDNMT1p itself, perhaps through its
association with the replication machinery or DNA repair pathways
(Guo et al., 2004; Leonhardt et al., 1992; Vertino et al., 2002). Our
recent observation that the xDNMT1-deficient phenotype is
independent of alterations in DNA methylation levels would support
this latter possibility (Dunican et al., 2008).
The functional properties of the methyl-CpG binding protein
MBD4 (MED1) suggest it as a possible candidate mediator of the
apoptotic response in xDNMT1-depleted embryos. Like other MBD
proteins, it has been shown to function as a methylation-dependent
transcription repressor, but it is also a thymine glycosylase and
interacts with the mis-match repair (MMR) protein MLH1 (Bellacosa
et al., 1999; Hendrich et al., 1999; Kondo et al., 2005; Parsons, 2003).
MBD4 thus, like DNMT1, potentially links epigenetic modification
mechanisms with the MMR pathway (Parsons, 2003; Guo et al.,
2004). An important function of MMR proteins is to sense DNA
damage and to mediate the decision to repair the lesion or to induce
apoptosis (Palii et al., 2008). The levels of several MMR proteins are
reduced in Mbd4–/– mouse embryonic fibroblasts, which can account
for the diminished apoptotic response of these cells to DNA-damaging
agents (Cortellino et al., 2003; Sansom et al., 2003). In wild-type cells,
DNA-damage recognition by MMR factors is sufficient to trigger cell
cycle arrest and apoptosis through direct interaction with signalling
kinases such as ATM, ATR, CHK1 and CHK2, which ultimately
activates p53 (Luo et al., 2004). In line with this observation, it has
been shown that overexpression of MLH1 induces apoptosis in cell
lines probably through its interaction with ATM (Luo et al., 2004;
Zhang et al., 1999).
Here we show that inhibition of xMBD4 function in early
Xenopus embryos reduces the phenotypical severity of xDNMT1
depletion, whereas microinjection of mouse Mbd4 mRNA induces
an apoptotic response that disrupts early development. In UVA laser
micro-irradiated cells, MBD4, MLH1 and DNMT1 can be
colocalised at sites of DNA damage. Our results are compatible with
a model in which MBD4 functions as an apoptotic-signalling
molecule through its direct interactions with DNMT1 and MLH1.
MATERIALS AND METHODS
Embryos and microinjections
Xenopus embryos were manipulated according to standard procedures
(Stancheva and Meehan, 2000). Two-cell embryos were injected with
antisense morpholino oligonucleotides (10 ng for DNMT1 and Kaiso, 5-10
ng for MBD4, MLH1 and p53, per embryo) or with RNA (0.2-1 ng for wild-
type mMBD4 and xMLH1 per embryo) synthesised by the mMessage
Machine kit (Ambion). The ability of morpholino oligonucleotides to
suppress translation was checked by the TNT Quick Coupled
Transcription/Translation Kit (Promega) using 1 μg of plasmid DNA and 4
μg of morpholino (Fig. S6 in the supplementary material). The following
morpholinos were used: xDNMT1 (xDMO1), GGACAGGCGT -
GAAACAGACTCGGC; xMBD4 (xM4MO), TCCGGCACAGGAGC -
AGCCATGTTTG; xMLH1 (xMLH1MO), CAGCCGCCGAAT AACT -
CCCGCCATT; xKaiso (xKMO), GATCAGCTTTTTTGTCTCCATGTCT;
xp53 (xp53MO), TGCCGGTCTCAGAGGAAGGTTCCAT.
DNA isolation and Southern blots
DNA from wild-type and microinjected embryos was isolated and 10 μg of
each sample were digested to completion with HpaII or MspI (MBI-
Fermentas) and electrophoresed in a 1% native agarose gel. DNA digests
were transferred to nylon membranes (Osmonics) and hybridised according
to the manufacturer’s protocols with a labelled 750-bp Xenopus satellite I
probe (Stancheva and Meehan, 2000; Stancheva et al., 2001).
Plasmids and constructs
Xenopus laevis MBD4 (AW641890), mouse MBD4 (BE335048 and
BE457540) and Xenopus DNMT1 (CA790804) clones were used along with
the Xenopus MLH1 clone DKFZp724LO463Q3. The full-length (477 amino
acid) protein, the glycosylase domain (307-477 amino acids) and the methyl-
CpG binding domain (55-133 amino acids) of xMBD4 were cloned into the
BamHI/SalI sites of pGEX-4T-1. The RFP-PCNA construct has been
described (Mortusewicz et al., 2005). The GFP-MLH1 expression vector
was constructed by cloning MLH1 cDNA into the pEGFP-C1 vector. A red
variant of the GFP-MLH1 expression vector was made by replacing GFP
with mCherry using NheI and BsrGI. The full-length T7-tagged xMBD4
expression construct was made by cloning into the XbaI-BamHI sites of
pCGT7 vector (Cazalla et al., 2005). The hDNMT1-FLAG construct was
obtained from W. Nelson (Agoston et al., 2005). The GFP-MBD4 construct
was obtained from A. Bird and mutated to make the catalytically dead
version GFP-MBD4D534A (Hendrich and Bird, 1998; Rai et al., 2008). The
GFP-xDNMT1 fusion was made by cloning full-lenth xDNMT1 into
pEGFP-C1. The MLH1-GFP construct was a gift from V. Cryns (Chen et al.,
2004). xDNMT1-GST fusions were made by cloning regions corresponding
to 1-130 amino acids, 124-380 amino acids and 505-600 amino acids into
the pGEX-4T-1 vector (GE Lifesciences).
Whole-mount TUNEL assay
Published procedures for the whole-mount TUNEL staining of embryos
were followed (Hensey and Gautier, 1997).
Protein interaction assays
GST-tagged fusions were expressed in the ER2566 E. coli strain, purified
using glutathione sepharose 4B and dialysed. GST pull-downs were
performed according to standard protocols using in vitro translated and 35S-
Met-labelled proteins. Samples were subjected to SDS-PAGE, transferred
to 3MM paper, dried and visualised by phosphorimaging. HeLa cells were
used for immunoprecipitation experiments. DNA constructs were
transfected with Lipofectamine 2000 (Invitrogene). Cells were analysed 24
hours after transfection. Immunoprecipitation was performed using the
Catch and Release v2.0 system (Upstate). Anti-T7-tagged antibody
(Novagen), anti-FLAG (Upstate) and monoclonal anti-GFP (CRUK)
antibodies were used.
Cell culture, transfection, FACs analysis, UVA laser
microirradiation and live imaging
Subcellular localisation studies using GFP and RFP fusion proteins were
done according to standard procedures, using p53–/– MEFs as recipients
(Lande-Diner et al., 2007). Cells were analysed 24 hours after
transfection. Positive signals were visualised with Alexa Fluor secondary
antibodies. Slides were examined using a Zeiss Axioplan II fluorescence
microscope with Plan-Neofluar objectives, a 100 W mercury source (Carl
Zeiss, UK) and a Chroma #84000 quadruple band-pass filter set (Chroma
Technology, Rockingham, VT, USA) with the excitation filters installed
in a motorised filter wheel (Ludl Electronic Products, USA). Grey-scale
images were captured with a Hamamatsu Orca AG CCD camera
[Hamamatsu Photonics (UK)] Instruments Pentamax). Image capture and
analysis were performed using in-house scripts written for IPLab
Spectrum (Scanalytics Corp, Fairfax, VA, USA). Transfection of
expression plasmids, microirradiation and live cell imaging was as
described (Mortusewicz et al., 2005; Mortusewicz et al., 2007). For
apoptosis analysis, primary mouse embryonic fibroblasts or HCT116 cells
were transfected using lipofectamine, stained with PE Annexin V (BD
Biosciences) 8-10 hours after transfection, sorted on BD FACSAria II
SORP sorter and analysed using BD FACs Diva software. The
percentages of annexin-positive cells in populations of GFP-positive and
GFP-negative cells were identified.
Rat and mouse DNMT1 analysis
Rat DNMT1 Myc-tagged constructs were kindly provided by Kunio Shiota
(Kimura and Shiota, 2003). Mouse DNMT1-GST fusions were obtained
from Sara Nakielny (Jeffery and Nakielny, 2004). Immunostaining was
performed according to standard techniques using p53–/– mouse embryonic
fibroblasts (MEFs) as recipients (Lande-Diner et al., 2007). Cells were











analysed 24 hours after transfection. A mouse monoclonal anti-T7 tag
antibody (Novagen) was used. Positive signals were visualised with Alexa
Fluor secondary antibodies. Slides were examined as described above.
RESULTS
xMBD4/xMLH1 mediate the apoptotic response in
xDMO morphants
Recently, we demonstrated that injection of a morpholino against
xDNMT1 (xDMO) into two-cell embryos results in premature
zygotic transcription before the mid-blastula transition (MBT) and
phenotypical abnormalities that mimic the effect of AS xDnmt1
RNA injection (Dunican et al., 2008; Stancheva et al., 2001).
However, the xDMO morphants do not exhibit any general changes
in DNA methylation levels (Fig. 1A) (Dunican et al., 2008). Despite
this, they undergo apoptosis, as evidenced by the appearance of
cellular shedding from the embryo surface and by TUNEL positivity
(Fig. 1B,C; Fig. 3B), features that we have previously characterised
for xDnmt1 AS RNA-injected embryos (Stancheva et al., 2001).
This suggests that global hypomethylation of DNA is not the trigger
for apoptosis and that an alternative pathway is responsible for
initiating programmed cell death when xDNMT1p levels are
reduced. We focused on the possible involvement of xMBD4 in
initiating apoptosis, as its murine counterpart has been implicated as
a central molecule in signalling pathways that are activated in
response to DNA damage and (like DNMT1) it is linked with the
MMR pathway (Cortellino et al., 2003; Parsons, 2003; Sansom et
al., 2003; Bellacosa et al., 1999; Hendrich et al., 1999).
We first tested by morpholino injection whether depletion of
xMBD4 or its binding partner xMLH1 could alleviate the effect of
xDNMT1 depletion. Fig. 2 shows a panel of control and injected
embryos (Fig. 2A-F) at equivalent stage 12-13. In comparison to
the wild-type embryos, the xDMO morphants show a high
proportion of abnormal embryos (70%), many of which display
characteristic white patches of shedding cells that are indicative of
apoptotic death (Fig. 2B). Higher magnification versions of Fig.
2A-F are available for clarity (see Fig. S1 in the supplementary
material). A very small proportion (2%) of the xDMO morphants
survive to develop to stage 30 (Fig. 2J,L), but in comparison to
wild-type controls have phenotypical defects that are indicative of
abnormal development, including spina bifida (compare Fig. 2J
and Fig. 2K). Co-injection of xDMO with either the xMBD4
(xM4MO) or the xMLH1 (xMLH1MO) morpholinos relieves the
severity of the phenotype (Fig. 2C,D). There are fewer obviously
apoptotic embryos and a higher proportion (65% and 60%,
respectively) have a normal appearance at the gastrula/neurula
stage (Fig. 2G,H,L). Indeed, many of these double-injected
embryos go on to form a high percentage (20% and 13%,
respectively) of normal stage 30 embryos when compared with
xDMO morphants (2%; Fig. 2L).
We had shown previously that targeted degradation of p53 levels
by human papilloma virus E6 protein (HPV-18E6) can rescue the
apoptotic response in AS RNA-depleted embryos (Stancheva et al.,
2001). As an additional control we also co-injected with xDMO a
morpholino against xp53 (xp53MO), which as predicted, rescued
the apoptotic phenotype induced by xDMO injection and led to a
high survival rate at gastrulation/neurulation (80%) and tadpole
stage (75%; Fig. 2E,L). However, none of the surviving
xDMO/xp53MO morphants had a normal appearance, and they
exhibited a reduction of trunk and posterior regions with relatively
small head structures by stage 30 (Fig. 2I). This is probably because,
in addition to its role in DNA-damage signalling pathways, xp53 is
required for proper mesoderm specification during Xenopus
development (Cordenonsi et al., 2003; Takebayashi-Suzuki et al.,
2003). As an additional control, we also co-injected an xKaiso
morpholino (xKMO) with xDMO, which is also required for pre-
MBT silencing (Ruzov et al., 2004). Unlike xM4MO, co-injection
with xKMO enhances cell death by gastrulation/neurulation with no
survivors at this stage (Fig. 2F). We conclude that either xMBD4 or
xMLH1 is specifically necessary for the activation of the apoptotic
pathway that results from xDNMT1 depletion.
Overexpression of xMBD4 or xMLH1 results in
apoptosis
Beause depletion of either xMBD4 or xMLH1 ameliorates the
apoptotic response that results from a decrease in xDNMT1 levels,
we hypothesised that overexpression of either protein would induce
the cell death pathway. To test this possibility, we microinjected
mRNAs (1 ng) for murine MBD4 (mMBD4) and MLH1 (mMLH1)
into two-cell embryos, allowing them to develop until equivalent
stage 12-13, and assayed them for apoptosis with the TUNEL assay.
In comparison to wild-type embryos, the mMBD4 and mMLH1
mRNA induced developmental arrest as exogastrulae and resulted
in hyper TUNEL-positive staining (Fig. 3A-D). For comparison, the
xDMO morphants showed less intense TUNEL staining and also an
exogastrulae phenotype at the equivalent stage (Fig. 3B). The effect
of mMBD4 overexpression is dose dependent, at a lower amount
(200 pg) the embryos went on to develop to tadpole stages but with
axial defects (see Fig. S2A,B in the supplementary material); none
of the high dose-injected embryos developed beyond gastrulation
2279RESEARCH ARTICLExDNMT1-mediated apoptosis
Fig. 1. xDMO morphants are not hypomethylated and exhibit an
apoptotic phenotype. (A) Southern blot analysis with the xSATI repeat
sequence demonstrating no hypomethylation at CCGG sites in xDMO
morphants (lanes 1 and 2). No enzyme (U), HpaII (H) and MspI (M)
restriction enzyme digests were performed on the indicated samples.
MspI is a methylation insensitive restriction enzyme, whereas HpaII is
methylation sensitive (C5mCGG). The digestion pattern of HpaII is
different to that of MspI in wild-type (WT) embryos, the latter gives rise
to fragments of 690 and 430 bp (arrows), indicating complete
digestion. The HpaII pattern is the same in WT, xDMO and embryos
injected with both xDMO and xM4MO (anti-xMBD4) morpholinos,
indicating high levels of DNA methylation at these repeats in all three
samples. (B) Phenotypes of wild type (WT) and xDNMT1 morpholino
(xDMO) embryos at stage 15. The xDMO morphants exhibit apoptotic
lesions (blue arrows) and a lack of neural folds (black arrows in WT)
compared with uninjected wild-type siblings or control morpholino-
injected embryos. (C) Post-stage 15 xDMO morphants exhibiting












(Fig. 3E,I). Injection of an equivalent dose of β-galactosidase
mRNA had no adverse effect on development (see Fig. S3 in the
supplementary material).
As additional proof that mMBD4 overexpression results in the
activation of a caspase-dependent pathway, we cultured the control
and mMBD4 mRNA-injected embryos in the presence of 20 μM Z-
DEVD-FMK (a caspase inhibitor), a concentration that does not
affect the development of control embryos (data not shown). This
ensured that a high proportion of the mMBD4 mRNA-injected
embryos (55%) developed to tadpole stage, although many of them
had axial defects that were similar to those observed for the low-
dose injection (Fig. 3E-G; see also Fig. S2A,B in the supplementary
material). In addition, the effect of mMBD4 overexpression (1 ng
mRNA) could be suppressed by the presence of either xp53MO or
xMLH1MO, which resulted in 27% and 18% survival, respectively,
by stage 30 (Fig. 3I). Furthermore, the presence of xM4MO reduced
the lethality of the mMBD4 mRNA injection, which suggests that
endogenous xMBD4 is recruited in the apoptotic response pathway
that is activated upon mMBD4 mRNA injection (Fig. 3H).
In agreement with these data, overexpression of either GFP-
MLH1 or GFP-MBD4 in transiently transfected primary mouse
embryonic fibroblasts (MEFs) resulted in activation of an apoptotic
response 2-4 (for MLH1) or 2-3 (for MBD4) times above that
caused by GFP alone (Fig. 3J). The glycosylase catalytic activity of
MBD4 is not required to activate apoptosis, as an inactive mutant,
GFP-MBD4D534A, also induced apoptosis in MEFs (Fig. 3J). This
suggests that the response is not activated through the DNA damage
that is potentially mediated by the glycosylase activity of MBD4. By
contrast, overexpression of GFP-MBD4 did not induce apoptosis in
HCT116 cells, which lack functional MLH1 (Papadopoulos et al.,
1994), whereas overexpression of GFP-MLH1 did induce apoptosis
in these cells (Fig. 3K). We conclude that MBD4 can signal an
apoptotic response in combination with MLH1, although it is not
clear how xDNMT1p depletion acts as a trigger for apoptotic
activation through xMBD4/xMLH1 (see model in Fig. S2C in the
supplementary material).
xMBD4 interacts with xDNMT1
Because hypomethylation is not required for the apoptotic response,
yet depletion of xDNMT1 is and the absence of xMBD4 or xMLH1
inhibits apoptosis, we hypothesised that the xMBD4 protein
interacts directly with xDNMT1. To test this idea, we co-expressed
tagged forms of either human DNMT1 (FLAG) or xDNMT1 (GFP)
with xMBD4 (T7) in HeLa cells and tested their interaction by
immunoprecipitation (IP) and subsequent western blotting. IP of
xMBD4 precipitates Xenopus and human DNMT1 (Fig. 4A; data
not shown). In the reverse experiment, IP of xDNMT1 or human
DNMT1 brings down xMBD4 (Fig. 4B). To test for a direct
RESEARCH ARTICLE Development 136 (13)
Fig. 2. The cell death phenotype of xDMO morphants can be alleviated by co-injection with either xMBD4, xMLH1 or xp53
morpholinos. (A,K) Uninjected control embryos at stages 12-13 and stage 30 (tadpole), respectively. (B,J) xDMO morphants at stage 13 and stage
30, respectively. Dying (apoptotic) embryos are indicated with a ‘+’ in B. (C,G) Embryos co-injected with xDMO and an anti-xMBD4 morpholino
(xM4MO) at stage 13 and stage 30, respectively. The mortality rate is reduced at stage 13 compared with that of embryos injected with xDMO only
(see graph in L). (D,H) Embryos co-injected with xDMO and an anti-xMLH1 morpholino (xMLH1MO) at stage 13 and stage 30, respectively. The
mortality rate is reduced at stage 13 compared with that of embryos injected with xDMO only (see graph in L) and the number of apoptotic
embryos is reduced. (E,I) Embryos co-injected with xDMO and an anti-xp53 morpholino (xp53MO) at stage 13 and stage 30, respectively. The
mortality rate is reduced at stage 13 and stage 30 compared with that of embryos injected with xDMO only (see graph in L), but the surviving stage
30 embryos have an abnormal appearance. (F) Embryos co-injected with xDMO and an xKaiso morpholino (xKMO) at stage 13 exhibit enhanced
embryo mortality. (L) The percentages of normal embryos and embryos with developmental defects at stage 13 and stage 34 following injection











interaction, we made a GST fusion of xMBD4 and investigated
whether it could pull down in vitro-translated xDNMT1. As a
positive control, we also tested the interaction between mouse
MLH1 and xMBD4 (Bellacosa et al., 1999); unsurprisingly, xMBD4
interacts with MLH1 via its C-terminal glycosylase domain (Fig.
4C), whereas the N-terminal MBD domain of MBD4 mediates its
interaction with xDNMT1 (Fig. 4C). We also mapped the MBD4-
interaction domain on DNMT1 from mouse, rat and Xenopus using
a combination of IP and GST pull-down experiments (see Fig. S4A-
C in the supplementary material). We could define a minimum
domain of approximately 70 amino acids in the N-terminal targeting
sequence (TS) region of DNMT1 that accounts for the MBD4
interaction (Fig. S4D in the supplementary material); interestingly,
this overlaps but is not the same as a region in rat DNMT1 that
interacts with MECP2 (Kimura and Shiota, 2003).
Previous work has shown that MBD4 localisation to
heterochromatin in mouse cells is methylation dependent (Hendrich
and Bird, 1998). We could also demonstrate by immunofluorescence
that epitope-tagged versions of xMBD4 localise at methylated
heterochromatic foci in p53–/– mouse embryonic fibroblast (MEF)
cells (to avoid inducing the apoptotic response), whereas MLH1 does
not (Fig. 4D; Fig. 5A). However, in the presence of xMBD4, MLH1
can be recruited to heterochromatin (Fig. 4E). DNMT1 associates
with chromatin during the G2 and M phases, and this association is
mediated by a specific targeting sequence that shows a strong
preference for constitutive but not facultative heterochromatin
(Easwaran et al., 2004). Interestingly, DNMT1 can colocalise with
xMBD4 at heterochromatic foci (Fig. 5A). By contrast, MLH1 is not
preferentially localised to constitutive heterochromatin in the presence
of overexpressed DNMT1, although there is some overlap when cells
are in G1 and S phases (Fig. 5B). Because MBD4 interacts with both
MLH1 and DNMT1 by independent domains, it is possible that
xMBD4 can act as a recruiter of MLH1 to chromatin sites that are
coincident with methylated DNA and DNMT1 during the cell cycle.
This possibility is borne out in triple transfection experiments in which
GFP-tagged DNMT1 can be colocalised with Cherry-tagged MLH1
in the presence of xMBD4 (Fig. 5C).
MBD4 and MLH1 accumulate at irradiated sites
Recent work suggests that DNMT1 participates in the MMR pathway
and can be recruited to sites of DNA damage by PCNA (Guo et al.,
2004; Mortusewicz et al., 2005). PCNA encircles double-stranded
DNA as a trimer, forming a sliding clamp that tethers proteins
involved in DNA replication and repair. We analysed the recruitment
kinetics of either GFP-MLH1 or GFP-MBD4 in the presence of RFP-
PCNA in HeLa cells (which do not have prominent heterochromatic
foci) sensitised by BrdU incorporation after inducing localised DNA
damage with a UVA laser micro-irradiation system (Mortusewicz et
al., 2005). Under these conditions, various types of DNA lesion are
generated leading to the recruitment of PCNA. As might be expected,
this also led to the recruitment of GFP-MLH1 to damaged sites, but
its accumulation lagged behind that of PCNA (Fig. 6A; see also
2281RESEARCH ARTICLExDNMT1-mediated apoptosis
Fig. 3. The apoptotic phenotype of MBD4-injected embryos can be inhibited with Z-DEVD-FMK, xM4MO, xMLH1MO and xp53MO.
(A-D) TUNEL staining (blue) indicates activation of apoptosis, compared with control embryos, in xDMO stage 12 morphants and embryos
microinjected with either MBD4 (mMBD4) or MLH1 (mMLH1) from mouse. (E) Phenotype of embryos injected with 1 ng of mMBD4 mRNA at stage
15 (neurulation). (F) Phenotype of embryos injected with 1 ng of mMBD4 mRNA and incubated with the caspase inhibitor Z-DEVD-FMK at stage 15.
(G) Phenotype of embryos injected with 1 ng of mMBD4 mRNA and incubated with the caspase inhibitor Z-DEVD-FMK at stage 30 (tadpole).
(H) Phenotype of embryos injected with 1 ng of mMBD4 mRNA and xM4MO at stage 30. (I) Percentages of normal embryos and embryos with
developmental defects at stage 13 and stage 34 overexpressing mMBD4 alone or in the presence of Z-DEVD-FMK, xMLH1MO or xp53MO.
(J,K) MEFs (J) or HCT116 cells (K) were transiently transfected with GFP-MBD4, GFP-MBD4D534A, GFP-MLH1 or GFP only, stained with PE annexin V
and analysed by FACS. The ratios between the percentages of apoptotic cells in GFP-positive versus GFP-negative cells are presented.
Overexpression of GFP-MBD4, GFP-MBD4D534A and GFP-MLH1 leads to the activation of apoptosis in MEFs, at least 2.5 times more than that












Movies 1-4 in the supplementary material). Likewise GFP-MBD4
was recruited to PCNA foci, but its retention in the presence of PCNA
was less stable than that of MLH1 (Fig. 6B; see Movies 1-4 in the
supplementary material). However, when GFP-MBD4 and Cherry-
MLH1 were co-transfected, both molecules were recruited to micro-
irradiated sites and maintained there during the 5-minute observation
period (Fig. 6C). In addition, RFP-DNMT1 and GFP-MBD4 could
localise to sites of DNA damage (Fig. 6D). These data suggest that the
interaction of these partners on chromatin is influenced by DNA
damage and that, while present at these lesions, it is possible that
MBD4 and DNMT1 can participate in the decision to either repair the
DNA damage (including the DNA methylation profile) or activate a
cell death program.
A catalytically inactive form of DNMT1 rescues the
cell death phenotype in AS RNA-injected embryos
The interaction between xMBD4/xMLH1 and xDNMT1 suggests a
model whereby loss of xDNMT1p releases or activates xMBD4 to
initiate the apoptotic program via xp53. It also suggests that
catalytically dead forms of DNMT1 might suppress the apoptotic
pathway, as this role appears to be independent of changes in DNA
methylation (Fig. 1) (Dunican et al., 2008). As shown previously,
AS RNA-injected embryos are severely depleted in xDNMT1
protein levels during early stages (stage 5-10), resulting in their
DNA becoming hypomethylated, and they exhibit high rates of
embryo lethality by stage 30 even though xDNMT1p levels are
restored by stage 11 (Stancheva and Meehan, 2000; Stancheva et al.,
2001) (Fig. 7A). Substitution of cysteine 1226 with tyrosine in the
catalytic site of human DNMT1 (hDNMT1C1226Y) results in an
enzyme with no methyltransferase activity (Jair et al., 2006). The
presence of either the wild-type or mutant hDNMT1 mRNA
substantially rescues the phenotypical deficits associated with
transient depletion of xDNMT1 before the MBT, with the
appearance of between 20-25% phenotypically normal embryos at
stage 30 (Fig. 7B,C) compared with the low number (4%) of
abnormal survivors observed following AS RNA-only injection.
This suggests that hDNMT1C1226Y can suppress activation of the
apoptotic pathway in AS RNA-injected embryos, and the
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Fig. 4. xMBD4 interacts directly with xDNMT1 and can also recruit MLH1 to methylated DNA present at constitutive heterochromatin.
(A) hDNMT1-FLAG injected by itself or with T7-tagged xMBD4 (T7xMBD4) was expressed in HeLa cells. Cell extracts were prepared and
immunoprecipitated with an anti-T7 monoclonal antibody (mAb) and subsequently western blotted with an anti-FLAG mAb. Lane 1; hDNMT1-
FLAG input; lane 2, T7xMBD4 and hDNMT1-FLAG IP; lane 3, hDNMT1-FLAG only immunoprecipitation (IP). An arrow indicates the hDNMT1-FLAG.
(B) A reciprocal IP was done between T7xMBD4 and either hDNMT1-FLAG or GFP-xDNMT1. Cell extracts were prepared and immunoprecipitated
with either an anti-GFP or anti-FLAG mAb and subsequently western blotted with an anti-T7 mAb. Lane 1, T7xMBD4 input; lane 2, T7xMBD4 and
GFP-xDNMT1 IP; lane 3, T7xMBD4 and hDNMT1-Flag IP; lane 4, T7xMBD4 only IP (anti-GFP). An arrow indicates the T7xMBD4 protein.
(C, left) Schematic of xMBD4 indicating its methyl-CpG binding (MBD) and glycosylase domains. The GST-fusion proteins used in pull-down assays
are shown underneath; FL, full length. (Right) Plasmids encoding either mouse MLH1 (mMLH1) or xDNMT1 were transcribed and translated in vitro,
and incubated with GST only or with the indicated GST-fusion proteins. After extensive washing, 35S-labelled bound proteins were resolved on SDS-
PAGE, dried and exposed. Notice the glycosylase region of xMBD4 interacts with mMLH1, and the MBD domain interacts with xDNMT1.
(D) Localisation of either MBD4-GFP or Cherry-MLH1 in the nucleus of mouse p53–/– MEFs. MBD4 (like endogenous mMBD4) is localised at
methylated heterochromatin, DAPI bright spots. By contrast, MLH1 shows general nuclear staining (like endogenous MLH1) (Schroering et al.,
2007). (E) Co-transfection of MBD4-GFP and Cherry-MLH1 into mouse p53–/– MEFs results in the recruitment of Cherry-MLH1 to methylated











subsequent phenotypical abnormalities. It also supports the idea that
DNA hypomethylation is not the trigger for apoptosis, as this cannot
be restored by hDNMT1C1226Y. Another feature of AS RNA-
injected embryos is the premature activation of transcription prior
to the MBT (stage 8.5) (Stancheva and Meehan, 2000). In contrast
to xDMO-rescued embryos in which xDNMT1p is depleted by
30-40% (Dunican et al., 2008), co-injection of either the
hDNMT1C1226Y or wild-type hDNMT1 (hDNMT1WT) with
xDNMT1 AS RNA was unable to restore pre-MBT silencing of
xBRA and xID2 to wild-type levels (Fig. 7D). This implies that the
premature transcription phenotype before the MBT (stage 8.5) and
the activation of apoptosis after MBT (stage 11 and later) are
independent processes, and that it is the latter mechanism that is
responsible for the phenotypical appearance of xDMO and AS RNA
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Fig. 5. MBD4 can target MLH1 to heterochromatic sites that also contain DNMT1. (A) Co-transfection of GFP-hDNMT1 and T7xMBD4 into
p53–/– MEFs results in their colocalisation at methylated heterochromatin, as indicated by the DAP1 bright spots (blue). (B) Co-transfection of GFP-
hDNMT1 and Cherry-MLH1 (Ch-MLH1) into p53–/– MEFs does not lead to the recruitment of Cherry-MLH1 to methylated heterochromatin, as
indicated by the DAP1 bright spots. The nuclear sub-localisation of DNMT1 in cells is cell cycle dependent and two major patterns are observed.
DNMT1 is either localised at late-replicating constitutive heterochromatin (lower panel) or is more evenly distributed (upper panel). There is some
overlap (as indicated by the merged signal) of MLH1 with DNMT1 in the upper panel, but not when DNMT1 is localised at methylated
heterochromatin (in late S phase or G2; lower panel). (C) By contrast, a triple transfection with GFP-hDNMT1,Cherry-MLH1 and T7xMBD4 (not
visualised) results in colocalisation of GFP-hDNMT1 and Cherry-MLH1 at methylated centromeric heterochromatin. MLH1 is resident at this region in
all transfectants, whereas hDNMT1 is either localised at late-replicating constitutive heterochromatin or is more generally localised (data not shown).
Fig. 6. Recruitment of MLH1, MBD4 and DNMT1
to sites of DNA damage. (A) Live cell imaging of
HeLa cells transiently transfected with RFP-PCNA and
GFP-MLH1 before (top) and after (bottom)
microirradiation. RFP-PCNA clearly colocalised with
GFP-MLH1 at the microirradiated site (arrows). (B) Live
cell imaging of HeLa cells transiently transfected with
RFP-PCNA (left) and GFP-MBD4 (right) during (top)
and after (bottom) microirradiation. RFP-PCNA clearly
colocalised with GFP-MBD4 at both microirradiated
sites (arrows). (C) Live cell imaging of HeLa cells
transiently transfected with Ch-MLH1 (left) and GFP-
MBD4 (right) before (top) and after (bottom)
microirradiation. Ch-MLH1 clearly colocalised with
GFP-MBD4 at the microirradiated site (arrows).
(D) Live cell imaging of HeLa cells transiently
transfected with RFP-DNMT1 (left) and GFP-MBD4
(right) during (top) and after (arrows). (D) Live cell
imaging of HeLa cells transiently transfected with
RFP-DNMT1 (left) and GFP-MBD4 (right) during (top)
and after (bottom) microirradiation. RFP-DNMT1
clearly colocalised with GFP-MBD4 at both
microirradiated sites (arrows). Merged pictures for
B-D are shown in the middle. The associated movies











mutant embryos. The inability to restore silencing in rescued AS
RNA embryos is in line with a model in which high levels of
DNMT1 are required during pre-MBT stages to maintain gene
repression (Dunican et al., 2008).
In Fig. 8A, we present a model for the activation of xDNMT1-
mediated apoptosis in Xenopus laevis embryos. We propose that a
chromatin-associated complex of xDNMT1, xMBD4 and xMLH1
in normal embryos responds to DNA damage or replication stress by
deciding either to repair the lesion or to activate an apoptotic
response through the activation/release of MBD4/MLH1 from
chromatin-bound xDNMT1. The MBD4/MLH1 complex signals,
probably via interaction with the DNA-damage kinases ATM and
ATR, activate the p53-dependent programmed cell death pathway.
Depletion of xDNMT1 triggers the apoptotic response by activation
of the pro-apoptotic MBD4/MLH1 complex (Fig. 8B). Removal of
either xMBD4 or xMLH1 prevents the activation of apoptosis in
xDMO morphants (Fig. 8C).
DISCUSSION
In previous work, we characterised the molecular pathology of
xDNMT1-depleted embryos, which exhibit the typical features of
programmed cell death, including DNA fragmentation, the
appearance of TUNEL-positive staining, caspase activation and
stabilisation of p53 levels (Stancheva et al., 2001). The induction of
14-3-3 proteins in these mutant embryos is consistent with the
activation of the G2 DNA damage cell cycle checkpoint. The cell
death phenotype of xDNMT1-depleted animal pole explants could be
suppressed by overexpression of either the anti-apoptotic protein Bcl2
or HPV-E6, an inhibitor of p53 function. Taken together, this suggests
that loss of the DNMT1 protein is linked with the cellular response to
DNA damage (checkpoint defects). Exposure of cells to 5-aza also
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Fig. 7. A catalytically inactive form of hDNMT1 can rescue embryos
severely depleted of xDNMT1. (A)Western blotting shows that
xDNMT1 levels are greatly reduced (>90%) in antisense (AS) xDnmt1
RNA-depleted stage 8 embryos (pre-MBT). This results in general DNA
hypomethylation, premature transcription and activation of apoptosis
(Stancheva and Meehan, 2000; Stancheva et al., 2001). In lane 2, four
embryo equivalents were loaded in a 1/5 dilution (0.8 embryo) for each
sample. The blots were stripped and reprobed with α-tublin antibodies as
a loading control. The cartoon indicates functional domains present in
human DNMT1 (hDNMT1), including the PCNA-binding domain (PCNA),
the Zn finger (CXXC) domain and catalytic domains. An inactive point
mutant of hDNMT1 (C1226Y, Mut hDNMT1) has no catalytic activity (Jair
et al., 2006). (B)Comparison of the percentage of normal and mutant
late tadpoles in control, AS RNA, AS and wild-type (WT) hDNMT1 mRNA,
and AS and mutant hDNMT1 mRNA-injected embryos. The rescued
embryos have a higher percentage of normal embryos than do the AS
RNA mutants. The rescuing ability of catalytically active and inactive forms
of hDNMT1 was comparable. (C)AS xDnmt1 RNA-depleted rescued
embryos are similar in phenotype to their control wild-type siblings.
Tadpole (stage 40) embryos are shown. Note the apoptosis in the low
number of surviving embryos injected with AS xDnmt1 RNA only (top
right). Co-injection of either wild-type hDNMT1 or mutant hDNMT1
mRNA can rescue AS RNA-injected embryos. Scale bar: 1 mm. (D) RNA in
situ hybridisation analysis reveals ectopic expression of the indicated
genes (xBRA and xID2) throughout the animal pole of AS RNA-injected,
but not control stage 8 embryos. Co-injection of either wild-type
hDNMT1 or mutant hDNMT1 mRNA cannot reimpose repression in AS
RNA-injected embryos. Scale bar: 1 mm.
Fig. 8. Model for the activation of xDNMT1-mediated apoptosis
in Xenopus laevis embryos. (A) In normal embryos, we propose that
a complex of xDNMT1, xMBD4 and xMLH1 is bound onto chromatin.
This complex plays a role in responding to DNA damage or replication
stress and is involved in the decision to repair the lesion or to activate
an apoptotic response by releasing MBD4/MLH1 from xDNMT1; the
MBD4/MLH1 complex signals probably via the DNA damage kinases
ATM and ATR. (B) In xDMO morphants, a reduction of xDNMT1p levels
results in abnormal activation (perhaps caused by release from a
chromatin-bound complex) of the p53 apoptotic pathway via unbound
MBD4/MLH1. (C) In xDMO/xM4MO or xDMO/xMLH1 double
morphants, the p53 apoptotic pathway cannot be activated owing to
the absence of the xMBD/xMLH1 complex. (D) Overexpression of MBD4











suggests that DNMT1 is a component of the DNA damage-response
system. This results in the robust induction of γ-H2AX, DNA
fragmentation, and the activation of repair proteins in both ATM and
ATR (DNA damage-response kinases) pathways (Palii et al., 2008).
DNMT1 is also strongly colocalised with γ-H2AX in 5-aza-treated
cells, which is consistent with its recruitment to sites of DNA damage
(Mortusewicz et al., 2005; Palii et al., 2008). A major question that
results from these observations is what is the initiating signal for
‘damage’ in the absence of DNMT1 in cell lines and embryos? An
obvious possibility is improper DNA re-methylation; however, our
experiments in which partial xDNMT1 depletion by morpholino
injection results in an embryonic lethal phenotype and activation of
the apoptotic pathway without any global or locus-specific changes in
DNA methylation suggests that this model is not applicable (Fig. 1A)
(Dunican et al., 2008). Like the effect of AS RNA depletion, the
xDMO morphants are TUNEL positive and the cell lethal phenotype
(but not the developmental defects) is rescued by inhibiting xp53
function (Fig. 3B; Fig. 2E,I). Similarly, the apoptotic response in
(Dnmt1–/–, p53–/–) MEFs is suppressed even though up to 10% of
genes are ectopically activated, including MBD4, caspase 1 and
caspase 4 (Lande-Diner et al., 2007). Our recent observation
demonstrating that a catalytically dead version of human DNMT1 can
rescue the embryonic (apoptotic) phenotype of xDMO morphants
suggested to us that the signal for apoptosis lies not with DNA
methylation but with xDNMT1 itself (Dunican et al., 2008).
As DNMT1 has been connected to the MMR and the DNA
damage-response pathways (Guo et al., 2004; Palii et al., 2008), we
considered what might functionally link xDNMT1 directly to these
pathways. We choose to focus on MBD4, as it promotes an apoptotic
response to DNA-damaging agents and excises spontaneously
deaminated cytosine (i.e. uracil) or methylcytosine (i.e. thymine) from
G-T/U mismatches (Cortellino et al., 2003; Hendrich et al., 1999;
Sansom et al., 2003). MBD4 also interacts with the MMR/tumor
suppressor gene (TSG) MLH1, and inhibition of MLH1 function also
causes increased apoptosis resistance with regard to DNA-damaging
agents, implying possible checkpoint and apoptotic signalling
functions for both proteins (Luo et al., 2004; Zhang et al., 1999;
Brown et al., 2003). Our double-depletion experiments (Fig. 2)
suggest that both xMBD4 and xMLH1 are required for the embryonic
lethal phenotype of xDMO morphants, which we attribute to their
ability to activate the apoptotic response (Fig. 1E,F; Fig. 3A-E). This
suggests a possible signalling pathway that connects DNMT1 to
MBD4/MLH1 and subsequently a DNA damage-sensing response.
MLH1 associates with the DNA-damage kinase ATM and MMR
complexes formed at sites of DNA damage facilitate the
phosphorylation of checkpoint kinases 1 and 2 by ATM (Bartek and
Lukas, 2003; Brown et al., 2003). ATM also directly phosphorylates
p53 at serine 15, contributing to its stabilisation and increased activity
as a transcription factor (Canman et al., 1998). The activation of p53
by these stimuli leads to the transcriptional modulation (both
activation and repression) of p53-target genes. In addition, p53
regulates cell cycle progression by controlling the G1-S and G2-M
checkpoints. Thus, p53 is an obvious candidate for mediating the
DNMT1-dependent apoptotic response (Bellacosa, 2001; Levine et
al., 2006). Phosphorylation of ATM is also observed after radiation-
induced DNA double-strand breaks that lead to activation of the G2/M
checkpoint and the double-strand break-response pathway (Shiloh,
2003). The potential colocalisation of DNMT1, MBD4 and MLH1
implies that they might participate in a cellular checkpoint that
monitors potential DNA hypomethylation events by a ‘proxy’
mechanism that detects the presence or absence of DNMT1, perhaps
at or adjacent to the replication fork (see Fig. S5 in the supplementary
material). The recruitment of these components in response to
localised DNA damage also suggests that they can have a role in the
cellular decision whether to repair the lesion or activate apoptosis (Fig.
8). We hypothesise that it is the absence of DNMT1 at this checkpoint
that triggers apoptosis by releasing MLH1/MBD4 to activate ATM in
mutant embryos and somatic cell lines. Interestingly, complete
inactivation of DNMT1 in HCT116 cancer cells also activates G2
arrest; however, most if not all of these DNMT1 mutant cells
eventually escape this arrest and exhibit mitotic defects, including
broken chromosomes, chromosome congression or alignment; defects
that result in mitotic catastrophe (Chen et al., 2007). It is possible that,
in agreement with our model, DNMT1-deficient HCT116 cells could
escape G2 arrest without the activation of apoptosis because they lack
functional MLH1, and that this contributes to the observed mitotic
catastrophe phenotype (Papadopoulos et al., 1994).
What is the potential importance of the mechanism that we have
identified? Cancers arise from the sequential acquisition of genetic
alterations in specific genes. The high number of mutations in cancer
cells led to the hypothesis that an early step in tumor progression is the
generation of genetic instability. The potential role of genetic
instability in the initiation and progression of colorectal cancers has
been well defined in the hereditary nonpolyposis colon cancer
syndrome (Bodmer, 2006). Constitutive activation of the DNA-
damage response is a feature of the pre-invasive stages of many
human tumors, including colorectal cancer (CRC), and this
checkpoint response is believed to delay or prevent the malignant
transformation of early lesions (Bartkova et al., 2005). MBD4 and
other MMR components are frequently mutated in CRCs that exhibit
micro-satellite instability (Miquel et al., 2007). These observations
suggest that DNMT1 is a crucial part of a signalling cascade that
activates an inducible barrier against tumour progression and genetic
instability resulting from replicative stress in pre-cancerous lesions or
the perturbation of epigenetic regulatory mechanisms during
development (Halazonetis et al., 2008). Cellular sensitivity to changes
in DNMT1 levels is thus lost when components of the signalling
cascade are either absent or mutated. In this context, it is notable that
cell cycle regulation of DNMT1 is often abrogated in tumor cells and
this has been suggested to be indicative of a poor prognosis (Agoston
et al., 2005; De Marzo et al., 1999; Saito et al., 2003).
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